Biogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.

GUIDANCE:

Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.

For earnings history and earnings-related data on Biogen (BIIB) click here.